ClinicalTrials.gg
RecruitingNCT05040074Updated Sep 10, 2021

SQ-Kyrin TMVr FIM Study

An interventional study of SQ-Kyrin Transcatheter Edge-to-Edge Valve Repair System in Mitral Regurgitation, sponsored by Shanghai Shenqi Medical Technology Co., Ltd. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-09-10.

Sponsored by Shanghai Shenqi Medical Technology Co., Ltd · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Oct 2022, 4 years 1 month ago, but the record still lists the study as recruiting.
  • Registered 4 months after the study started (first participant enrolled Apr 2021, registered Aug 2021).
  • Started Apr 2021; still recruiting 5 years 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
20
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 57 studies in Mitral Valve Insufficiency with a site in China — 44 open to participants now, 46 under way, none of them phase 3. Mitral Valve Insufficiency · China.

Planned enrollment
34th of 40
20 · median 127
Started
2021
with 6 others
No phase
36 of 57
29 open now
Primary completion
2022-10
later than 0 of 45 live
Registered
9th of 57
by date
Lead sponsor
3 of 57
Shanghai Shenqi Medical Technology Co., Ltd

Among the 57 studies in Mitral Valve Insufficiency with a site in China, this one is the 34th largest by planned enrollment of the 40 interventional ones that give a count, is one of 7 that started in 2021, is one of 36 with no phase, reaches primary completion later than 0 of the 45 other live ones, and was the 9th registered.

Mitral Valve Insufficiency

471 studies on the registry are indexed under Mitral Valve Insufficiency; 165 are open to participants now.

Browse Mitral Valve Insufficiency studies →

Open to participants now

44 of the 57 studies in Mitral Valve Insufficiency with a site in China are open now. Recruiting first, the newest first:

39 more — sign in →

All 44 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 121 Mitral Valve Insufficiency studies recruiting now, 100 (83%) set no upper age limit and 6 (5%) stop at 75 or younger; 12 take children under 18; 1 takes healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 57 studies in Mitral Valve Insufficiency with a site in China, or all of them as a file.
02

Study summary

A feasibility study to evaluate the effectiveness and safety of the SQ-Kyrin Transcatheter Edge-to-Edge Valve Repair System for the treatment of moderate-to-severe mitral regurgitation in patients with high surgical risk.

Read the detailed description

This is a prospective, multicenter, single-arm observation, feasibility clinical study that plans to enroll a total of not less than 10 and not more than 30 patients, adopts the post-op immediate technical success rate as the primary endpoint, and uses the all-cause mortality at 30 days post-op, incidence of serious adverse event at 30 days post-op, device success rate at 30 days post-op, and procedural success rate at 30 days post-op as secondary endpoints to evaluate the effectiveness, safety, and feasibility of the Transcatheter Edge-to-Edge Valve Repair System of Shanghai Shenqi Medical Technology Co., Ltd. in clinical use and preliminarily evaluate the product's performance. A phasic study report (for phasic data summary and analysis) will be issued after completion of the 30-day postoperative follow-up to evaluate the effectiveness, safety, and feasibility of the device and apply for clinical studies before official registration and marketing. In the meantime, patients enrolled will continue to be followed up for 6 months and 1-5 years post-op to evaluate the long-term effect of the mitral valve repair system.

03

Conditions studied

  • Mitral Regurgitation

Keywords

  • Mitral Regurgitation
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Severe mitral valve regurgitation ≥ 3+ (moderate-to-severe mitral regurgitation disease);
  2. Patients with high or prohibitive risk for conventional open thoracic surgery as defined by STS risk scoring result; subjects who are judged as not tolerating mitral valve surgery due to STS procedural mortality risk ≥ 8% for mitral valve replacement or presence of any of the following risk factors:

    1. Porcelain aorta or active ascending aortic atheroma
    2. Prior radiation therapy to mediastinum
    3. History of mediastinitis
    4. (LVEF) \< 40%
    5. Presence of unobstructed coronary artery bypass graft
    6. History of 2 or more cardiothoracic surgeries
    7. Liver cirrhosis
    8. Other surgical risk factors
  3. Degenerated MR patients, or functional MR patients who have received guideline-directed medical therapy (GDMT therapy)
  4. Age ≥ 18 years, male or female;
  5. Patients who are at extremely high risk or not suitable for conventional mitral valve surgery, as assessed by a multidisciplinary heart team (including at least one cardiac surgeon and one cardiologist);
  6. Anatomically suitable for transcatheter mitral valve repair by edge-to-edge technique and can be treated by the SQ-Kyrin device;
  7. Patients who can understand the objectives of the trial, volunteer to participate in the study, sign the form, and are willing to receive related examinations and clinical follow-up.

Exclusion criteria

Exclusion Criteria:

  1. History of cardiac and mitral valve surgeries;
  2. Infective endocarditis or evidence of active infection;
  3. Mitral valve stenosis;
  4. Severe uncontrolled coronary artery disease;
  5. Pulmonary artery hypertension (systolic pulmonary artery pressure > 70 mmHg);
  6. Severe right cardiac insufficiency;
  7. \< 30%;
  8. Cardiac function of Class IV;
  9. Patient is extremely week to tolerate surgery under general anesthesia, or in a shock state indicating circulatory support;
  10. Hypertrophic cardiomyopathy, restrictive cardiomyopathy, or constrictive pericarditis;
  11. Chronic dialysis;
  12. Definite coagulation disorder and severe coagulation system diseases;
  13. Clear for use of anticoagulants;
  14. Cerebral stroke or in the past 30 days;
  15. Any cardiac mass, left ventricular or atrial thrombosis identified by echocardiography;
  16. Other valve diseases that requiring surgery or intervention;
  17. Severe macrovascular disease requiring surgical treatment;
  18. Treatment-naive carotid artery stenosis > 70%;
  19. Imaging evidence of inappropriate cardiac and valve anatomy;
  20. Known to contrast media, and nickel-titanium memory alloy products;
  21. Severe nervous system disorder compromising the cognitive ability;
  22. \< 12 months;
  23. Severe thorax deformity;
  24. Pregnant and lactating women.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
20 participants (estimated)

Study arms

  • Experimental
    SQ-Kyrin TMVr Feasibility Study

    Experimental group is allocated to use the transcatheter edge-to-edge valve repair system of Shanghai Shenqi Medical Technology Co., Ltd.

    Device: SQ-Kyrin Transcatheter Edge-to-Edge Valve Repair System

Interventions

  • DeviceSQ-Kyrin Transcatheter Edge-to-Edge Valve Repair System

    Transesophageal echocardiography-guided, implantable mitral valve clip repair system

06

What researchers measure

Primary outcomes

  1. Incidence of acute procedural success

    Must meet all the four items:1)no procedural mortality; 2)success in delivery and retrieval of the device delivery system; 3)successful deployment and accurate positioning of the device; 4)no emergency surgery or reintervention related to the device or surgical approach

    Time frame: Immediate postoperative

Secondary outcomes

  1. All-cause mortality

    Death from any cause

    Time frame: 1 month

  2. Incidence of serious adverse event(SAE)

    If the adverse event meets any of the criteria below, it is regarded as a serious adverse event (SAE): 1) results in death; 2) is life threatening, results in illness or injury; 3) requires inpatient hospitalization or prolongation of existing hospitalization; 4) results in a persistent or significant disability/incapacity; 5) results in a congenital anomaly/birth defect, fetal death, fetal distress; 6) results in medical or surgical intervention to prevent permanent impairment to body structure or a body function; 7) an important medical event that may not result in death, be life-threatening, or require hospitalization but may be considered serious when, based upon appropriate medical judgment, may jeopardize the patient or subject and/or may require intervention to prevent one of the outcomes listed in this definition.

    Time frame: 1 month

  3. Device success rate

    Definition of device success(must meet all the four items) :1) No procedural mortality or stroke;2) Proper deployment and positioning of the device;3) No emergency surgery or reintervention related to the device or surgical approach;4) The implanted mitral valve repair system achieves the following safety and effectiveness indicators: * No evidence of structural or functional abnormality * No device-related technical failure or complication * Significant functional improvement after valve repair, without significant stenosis (post-op EOA ≥ 1.5 cm2 and transvalvular pressure gradient \< 5 mmHg/valve regurgitation ≤ Grade 2+/no device-related hemolysis)

    Time frame: 1 month

  4. Procedural success rate

    Definition of procedural success(must meet the two items):1) Device success;2) Absence of the following severe complications: death; stroke; life-threatening hemorrhage; severe vascular complications; secondary severe organic heart diseases (e.g.: aortic dissection, left atrium/auricle rupture, left ventricular outflow tract obstruction, etc.); Grade II-III and above renal insufficiency; myocardial infarction or coronary ischemia requiring percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG); severe hypotension, heart failure, respiratory failure requiring use of high-dose vasoactive medications/mechanical acids; any valve-related dysfunctions, including repair device detachment (single or two valve leaflets)/embolism/device-related autologous mitral valve damage/other conditions requiring second intervention.

    Time frame: 1 month

07

Study locations

1 of 1 sites recruiting
08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2021 (actual). Primary completion is estimated for Oct 2022, 18 months after the start.

Of 91 industry-sponsored interventional studies with no phase under Mitral Valve Insufficiency, half reached primary completion within 59 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 144. This study's planned 18 months is below that.

Counting every sponsor, half of 144 studies reached it within 56 months; a quarter within 25 and three quarters within 108.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 12, 2021
First posted
Sep 10, 2021
StartActual
Apr 1, 2021
Primary completionEst.
Oct 2022
CompletionEst.
Oct 2026
Last update
Sep 10, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 10, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05040074
Lead sponsor
Shanghai Shenqi Medical Technology Co., Ltd
Responsible party
Sponsor
First posted
Sep 10, 2021
Start date
Apr 1, 2021
Primary completion
Oct 2022 (estimated)
Completion
Oct 2026 (estimated)
Last update
Sep 10, 2021

Study contacts

Grace Gu
Contact
guchaojun@sqmedical.com
13636491192

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion